The FDA has approved Uplizna (inebilizumab-cdon) for the treatment of immunoglobulin G4-related disease in adult patients.

Postoperative pain and opioid consumption were increased among patients who underwent TKA but decreased among those who underwent THA.

Men with gout and obesity receiving febuxostat-based ULT were less likely to achieve SU targets and more frequently experienced disease flares.

Degenerative disc disease is common among young adults with PsA, with key risk factors including older age, male sex, diabetes, and inflammatory back pain.

Based on clinical trial data, abatacept was not associated with increased malignancy risks in RA or PsA; observational data indicated a higher risk vs other b/tsDMARDs.

The recombinant zoster vaccine protects against HZ and PHN in older patients with RA, with no increased risk for RA flares found within 30 days of vaccination.